Clinical Trial Update: Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports safety and pharmacokinetic data for a modified tafasitamab intravenous dosing regimen in combination with lenalidomide for re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Monjuvi (tafasitamab)
• Revlimid (lenalidomide)

Snippet

Sponsor: Incyte Corporation | Conditions: Diffuse Large B Cell Lymphoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-07-28